You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

Patent: 5,509,905


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,509,905
Title: Injector display
Abstract:The invention concerns a display for a medical injection device (1) wherein an injection dose is pre-selected by rotating an operating head (2) and then is administered by axially displacing said head. Switching devices (7, 8) are apposed to the operating head (2) to actuate switches (7, 8) of which the switch positions are transmitted to a printed circuit board (13). The printed circuit board (13) preferably contains a processor, so that values such as set injection dose, the sum of administered injection doses etc. and signals concerning operational states are shown on a display system (15).
Inventor(s): Michel; Peter (Burgdorf, CH)
Assignee: Medimpex Ets (LI)
Application Number:08/133,125
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,509,905

Introduction

United States Patent 5,509,905, titled "Injector Display," is a patent that was granted for an invention related to the display of information on an injector device. To understand the significance and validity of this patent, it is crucial to delve into the claims, the patent landscape, and the relevant legal and technical frameworks.

Overview of the Patent

Patent Details

The patent in question, US 5,509,905, was issued for an "Injector Display" and is associated with the publication number US5509905A. This patent pertains to a device designed to display information related to the injection process, such as the amount of substance injected, the rate of injection, and other relevant parameters[4].

Claims Analysis

Claim Structure

The claims of a patent are the most critical part, as they define the scope of the invention and the rights granted to the patent holder. For US 5,509,905, the claims would typically include a combination of independent and dependent claims that outline the specific features and functionalities of the injector display.

Novelty and Non-obviousness

To be patentable, an invention must meet the criteria of novelty and non-obviousness as defined by 35 U.S.C. §102 and §103, respectively. The novelty requirement ensures that the invention is not fully anticipated by prior art, meaning it must not have been previously disclosed in any form[3].

For the "Injector Display" patent, the examiner would have evaluated whether the claimed invention was novel by comparing it against prior art. If the invention was found to include elements that were not previously disclosed, it would have met the novelty requirement.

Non-obviousness requires that the invention is not an evident solution to someone skilled in the field. The patent examiners assess this by comparing the invention against prior art to determine if it offers innovative steps that are not readily apparent[2].

Usefulness and Patentable Subject Matter

The invention must also be useful and fall within the category of patentable subject matter. According to 35 U.S.C. §101, the invention must be operable and provide some tangible benefit. For an injector display, this would involve demonstrating that the device serves a practical purpose, such as enhancing the safety or efficiency of the injection process[1].

Patent Landscape and Legal Framework

U.S. Patent System Overview

The U.S. patent system, governed by Title 35 of the U.S. Code, is designed to promote innovation by granting exclusive rights to inventors for a limited time. The United States Patent and Trademark Office (USPTO) is responsible for administering this system, ensuring that patents are issued only for inventions that meet the statutory requirements of novelty, non-obviousness, and utility[1].

Patent Trial and Appeal Board (PTAB)

The PTAB, established by the America Invents Act (AIA), provides a mechanism for challenging the validity of issued patents. While this patent was issued before the AIA, understanding the PTAB's role is crucial for any patent's long-term validity. The PTAB can review patents for grounds such as anticipation, where the claimed invention is found in prior art, and non-obviousness[1].

Case Law and Precedents

Supreme Court decisions, such as Alice Corp. v. CLS Bank International and Bilski v. Kappos, have significantly shaped the patentability of inventions, especially those involving abstract ideas or mathematical formulas. These decisions emphasize that patents must be tied to specific technological implementations or practical applications to be valid[2].

Impact on Innovation and Competition

Competitive Advantage

Patenting an invention like the "Injector Display" can provide a competitive advantage by granting exclusive rights to the inventor. This exclusivity can incentivize firms to invest more in research and development, as they can recoup their investment through the exclusive use of the patented technology[2].

Potential Barriers to Innovation

However, patenting can also stifle innovation if it prevents others from building upon the patented invention. Competitors may face legal barriers, reducing the diversity of technological solutions available in the market. The lengthy and expensive patenting process can also discourage smaller firms from participating in certain technological advancements[2].

Examination Process

Role of Patent Examiners

The USPTO assigns patent examiners to evaluate the patent application. These examiners review the documentation, search prior art, and verify the novelty and non-obviousness of the invention. Initial feedback, often in the form of an "office action," may include rejections or requests for additional information. Engaging promptly with the examiner is crucial to address concerns and provide necessary clarifications[2].

Anticipation and Prior Art

Application of 35 U.S.C. 102

A claimed invention can be rejected under 35 U.S.C. 102 if it is anticipated by prior art. This means that every element required by the claim must be found in a single prior art reference. The disclosure must teach every element of the claim under its broadest reasonable interpretation[3].

For the "Injector Display" patent, the examiner would have ensured that the claimed invention was not anticipated by any prior art, including patents, publications, or other state of the art knowledge.

Design Patents and Challenges

PTAB Decisions on Design Patents

While US 5,509,905 is a utility patent, understanding the trends in design patents can provide insights into the broader patent landscape. Design patents have a lower institution rate for inter partes review or post-grant review compared to utility patents. However, when instituted, these reviews often result in the invalidation of the challenged design patent based on prior art, particularly on grounds of anticipation[5].

Key Takeaways

  • Novelty and Non-obviousness: The "Injector Display" patent must have met the criteria of novelty and non-obviousness to be granted.
  • Usefulness and Patentable Subject Matter: The invention must be useful and fall within the category of patentable subject matter.
  • Patent Landscape: The patent is part of a broader landscape influenced by Supreme Court decisions and PTAB reviews.
  • Impact on Innovation: Patenting can both incentivize and stifle innovation depending on how it is managed.
  • Examination Process: The role of patent examiners is critical in ensuring the patent meets all statutory requirements.

FAQs

Q: What are the main criteria for a patent to be granted in the U.S.?

A: The main criteria include novelty, non-obviousness, utility, and falling within the category of patentable subject matter.

Q: How does the USPTO determine if an invention is novel?

A: The USPTO determines novelty by comparing the claimed invention against prior art to ensure it is not fully anticipated by any previous disclosure.

Q: What is the role of the Patent Trial and Appeal Board (PTAB)?

A: The PTAB reviews challenges to the validity of issued patents, including grounds such as anticipation and non-obviousness.

Q: Can algorithms be patented?

A: Yes, algorithms can be patented, but the patent must cover the specific application of the algorithm in a process or device, not the algorithm itself.

Q: How do Supreme Court decisions impact patent law?

A: Supreme Court decisions, such as Alice Corp. v. CLS Bank International, shape the landscape by defining what constitutes a patentable invention, particularly in the context of abstract ideas and technological implementations.

Sources

  1. Congressional Research Service, "Patents and Innovation Policy," June 25, 2022.
  2. Patent Lawyer, "Can You Patent an Algorithm? Understanding Legal Boundaries," June 20, 2024.
  3. USPTO, "2131-Anticipation — Application of 35 U.S.C. 102," Manual of Patent Examining Procedure.
  4. Google Patents, "US5509905A - Injector display."
  5. Sterne Kessler, "Design Patents Continue to Escape Challenges," March 1, 2022.

More… ↓

⤷  Subscribe

Details for Patent 5,509,905

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 April 20, 2000 5,509,905 2013-04-23
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 April 25, 2007 5,509,905 2013-04-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.